| 产品描述: | JNJ-1661010是一种有效的,选择性的FAAH抑制剂,IC50分别为10 nM(大鼠)和12 nM (人类),作用于FAAH-1比作用于FAAH-2选择性高100倍以上。 |
| 靶点: |
IC50: 34 nM (rat FAAH) and 33 nM (human FAAH) |
| 体内研究: |
JNJ-1661010 (Takeda-25; i.p.; 50 mg/kg) diminishes thermal hyperalgesia in the inflammatory rat carrageenan paw model. JNJ-1661010 (i.p.; 10 mg/kg) has a T1/2 of 35 mins, a CL of 0.032 mL/min/kg, and a Cmax of 1.58 μM for rats. |
| 参考文献: |
1. Keith JM, et al. Thiadiazolopiperazinyl ureas as inhibitors of fatty acid amide hydrolase. Bioorg Med Chem Lett. 2008 Sep 1;18(17):4838-43. 2. Karbarz MJ, et al. Biochemical and biological properties of 4-(3-phenyl-[1,2,4] thiadiazol-5-yl)-piperazine-1-carboxylicacid phenylamide, a mechanism-based inhibitor of fatty acid amide hydrolase. Anesth Analg. 2009 Jan;108(1):316-29. |
| 溶解性: |
Soluble in DMSO (36 mg/ml at 25 °C), water (<1 mg/ml at 25 °C), and ethanol (<1 mg/ml at 25 °C). |
| 保存条件: |
2-8℃ |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.736 ml |
13.682 ml |
27.364 ml |
| 5 mM |
0.547 ml |
2.736 ml |
5.473 ml |
| 10 mM |
0.274 ml |
1.368 ml |
2.736 ml |
| 50 mM |
0.055 ml |
0.274 ml |
0.547 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |